Abbasi Muhammad Shahmir, Afzal Muhammad Zubair, Sarwar Tayyaba, Gamlen-Steves Holly A
Department of Geriatric Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
Comprehensive Breast Program, Department of Medical Oncology, Dartmouth Cancer Center, Lebanon, NH 03755, USA.
Cancers (Basel). 2025 Aug 26;17(17):2788. doi: 10.3390/cancers17172788.
HER2-positive breast cancer represents a biologically aggressive subtype associate with poor prognosis, despite advances in targeted therapies. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), initially approved for hormone-receptor-positive, HER2-negative disease, are now being explored in HER2-positive settings due to their mechanistic synergy with the HER2 signaling pathway. This review synthesizes evolving clinical evidence from trials and highlights further research into biomarker discovery. CDK4/6i may redefine treatment paradigms in HER2-positive breast cancer, offering a potential, non-chemotherapy option with durable benefit in select patient populations.
尽管靶向治疗取得了进展，但人表皮生长因子受体2（HER2）阳性乳腺癌是一种具有生物学侵袭性的亚型，预后较差。细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）最初被批准用于激素受体阳性、HER2阴性疾病，由于其与HER2信号通路的机制协同作用，目前正在HER2阳性患者中进行探索。本综述综合了试验中不断发展的临床证据，并强调了对生物标志物发现的进一步研究。CDK4/6i可能会重新定义HER2阳性乳腺癌的治疗模式，为特定患者群体提供一种潜在的、具有持久益处的非化疗选择。
